Glycosylation and size of IgA1 are essential for interaction with mesangial transferrin receptor in IgA nephropathy
- PMID: 14978164
- DOI: 10.1097/01.asn.0000115401.07980.0c
Glycosylation and size of IgA1 are essential for interaction with mesangial transferrin receptor in IgA nephropathy
Abstract
Transferrin receptor (TfR) has been identified as a candidate IgA1 receptor expressed on human mesangial cells (HMC). TfR binds IgA1 but not IgA2, co-localizes with mesangial IgA1 deposits, and is overexpressed in patients with IgA nephropathy (IgAN). Here, structural requirements of IgA1 for its interaction with mesangial TfR were analyzed. Polymeric but not monomeric IgA1 interacted with TfR on cultured HMC and mediates internalization. IgA1 binding was significantly inhibited (>50%) by soluble forms of both TfR1 and TfR2, confirming that TfR serves as mesangial IgA1 receptor. Hypogalactosylated serum IgA1 from patients with IgAN bound TfR more efficiently than IgA1 from healthy individuals. Serum IgA immune complexes from patients with IgAN containing aberrantly glycosylated IgA1 bound more avidly to TfR than those from normal individuals. This binding was significantly inhibited by soluble TfR, highlighting the role of TfR in mesangial IgA1 deposition. For addressing the potential role of glycosylation sites in IgA1-TfR interaction, a variety of recombinant dimeric IgA1 molecules were used in binding studies on TfR with Daudi cells that express only TfR as IgA receptor. Deletion of either N- or O-linked glycosylation sites abrogated IgA1 binding to TfR, suggesting that sugars are essential for IgA1 binding. However, sialidase and beta-galactosidase treatment of IgA1 significantly enhanced IgA1/TfR interaction. These results indicate that aberrant glycosylation of IgA1 as well as immune complex formation constitute essential factors favoring mesangial TfR-IgA1 interaction as initial steps in IgAN pathogenesis.
Similar articles
-
Engagement of transferrin receptor by polymeric IgA1: evidence for a positive feedback loop involving increased receptor expression and mesangial cell proliferation in IgA nephropathy.J Am Soc Nephrol. 2005 Sep;16(9):2667-76. doi: 10.1681/ASN.2004111006. Epub 2005 Jun 29. J Am Soc Nephrol. 2005. PMID: 15987753
-
Transferrin receptor engagement by polymeric IgA1 induces receptor expression and mesangial cell proliferation: role in IgA nephropathy.Contrib Nephrol. 2007;157:144-7. doi: 10.1159/000102457. Contrib Nephrol. 2007. PMID: 17495453 Review.
-
Binding capacity and pathophysiological effects of IgA1 from patients with IgA nephropathy on human glomerular mesangial cells.Clin Exp Immunol. 2004 Apr;136(1):168-75. doi: 10.1111/j.1365-2249.2004.02408.x. Clin Exp Immunol. 2004. PMID: 15030528 Free PMC article.
-
Increased binding of polymeric lambda-IgA to cultured human mesangial cells in IgA nephropathy.Kidney Int. 1996 Mar;49(3):839-45. doi: 10.1038/ki.1996.116. Kidney Int. 1996. PMID: 8648928
-
Role of IgA receptors in the pathogenesis of IgA nephropathy.J Nephrol. 2016 Feb;29(1):5-11. doi: 10.1007/s40620-015-0246-5. Epub 2015 Nov 14. J Nephrol. 2016. PMID: 26572664 Review.
Cited by
-
Immunoglobulin Glycosylation Effects in Allergy and Immunity.Curr Allergy Asthma Rep. 2016 Nov;16(11):79. doi: 10.1007/s11882-016-0658-x. Curr Allergy Asthma Rep. 2016. PMID: 27796794 Review.
-
Pathogenesis of IgA nephropathy.Nat Rev Nephrol. 2012 Mar 20;8(5):275-83. doi: 10.1038/nrneph.2012.58. Nat Rev Nephrol. 2012. PMID: 22430056 Review.
-
IgA vasculitis with nephritis: update of pathogenesis with clinical implications.Pediatr Nephrol. 2022 Apr;37(4):719-733. doi: 10.1007/s00467-021-04950-y. Epub 2021 Apr 5. Pediatr Nephrol. 2022. PMID: 33818625 Free PMC article. Review.
-
FcαRI binding at the IgA1 CH2-CH3 interface induces long-range conformational changes that are transmitted to the hinge region.Proc Natl Acad Sci U S A. 2018 Sep 18;115(38):E8882-E8891. doi: 10.1073/pnas.1807478115. Epub 2018 Sep 4. Proc Natl Acad Sci U S A. 2018. PMID: 30181292 Free PMC article.
-
IgA Vasculitis with Nephritis in Adults: Histological and Clinical Assessment.J Clin Med. 2021 Oct 22;10(21):4851. doi: 10.3390/jcm10214851. J Clin Med. 2021. PMID: 34768371 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous